Method of treating patients suffering pulmonary tuberculosis. RU patent 2456006.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to phthisiology, and may be used for treating patients with pulmonary tuberculosis. That is ensured by conducting the tuberculosis therapy in compliance with the standard schedules and additionally prescribing the probiotic biologically active additive SimBiovital 9.0 g in a single dose every second day with food for two months, and also the Hepel 1 tablet once a day sublingually daily for four months.

EFFECT: method provides higher clinical effectiveness in pulmonary tuberculosis as indicated by infiltration resolution, cavity closure and abacillation with reduced rate of developing adverse hepatotoxic reactions and disbiotic intestinal disorders.

3 tbl, 2 ex

IPC classes for russian patent Method of treating patients suffering pulmonary tuberculosis. RU patent 2456006. (RU 2456006):

A61P11 - Drugs for disorders of the respiratory system

A61K36/28 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

A61K35/66 - Materials from micro-organisms

Another patents in same IPC classes:

Preparation preventing development of abnormalities in lung tissue under cytostatic impact / 2455991
Claimed is application of neuroleptic haloperidol as means able to prevent development of abnormalities in lung tissue, caused by introduction of cytostatics. Reduction in development of inflammatory response due to reduction of development of connective tissue (pneumofibrosis) in lungs at the background of bleomicin introduction is shown.

Substituted isoquinoline and isoquinolinone derivatives as rho-kinase inhibitors / 2455302
Invention relates to 6-substituted isoquinoline and isoquinolone derivatives of formula (I) where R1 denotes OH; R2 denotes H; R3 denotes H; R4 denotes H, (C1-C6)alkyl; R5 denotes H, halogen; R6 denotes H, (C1-C8)alkyl, (C1-C6)alkyleneR', (C1-C6)alkylene-C(O)NH-(C1-C6)alkyl, (C1-C6)alkylene-C(O)O-(C1-C6)alkyl, C(O) (C1-C6)alkyl, C(O)R1 or C(O)-(C1-C6)alkyleneR'; R7 denotes H, halogen, (C1-C6)alkyl; R8 denotes H; n equals 1, 2, 3 or 4; m equals 1, 2, 3, 4 or 5; and L denotes O or O-(C1-C6)alkylene; where R' denotes (C3-C8)cycloalkyl, (C5-C10)heterocyclyl, (C6-C10)aryl; where in residues R4, R6 and R7 alkyl or alkylene can optionally be substituted once or several times with OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONHCH3 or CON(CH3)2; where in residues R4, R6 and R7 alkyl or alkylene can optionally be substituted once or several times with halogen; where in residue R6(C6-C10)aryl and (C5-C10)heterocyclyl are unsubstituted or substituted once or several times with suitable groups independently selected from halogen; where, if m equals 3, R6 does not denote H; and where, if m equals 3 and R6 denotes a residue selected from (C1-C8)alkyl, (C1-C6)alkylene-R'; alkyl, alkylene in said residue is substituted with once or several times, preferably once to three times, with OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONHCH3 or CON(CH3)2; or stereoisomeric forms thereof and/or tautomeric forms thereof and/or pharmaceutically acceptable salts thereof. The invention also relates to use of compounds of formula I to prepare a medicinal agent which inhibits Rho-kinase, as well as to the medicinal agent itself.

4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazolone-7-yl compounds for modulation of β2-adrenoreceptor activity / 2455295
Present invention refers to new benzothiazolone derivatives of formula (I) or to their pharmaceutically acceptable salts showing β2-adrenoreceptor agonist activity, to a method for producing and using them for preparing a drug. wherein Ra and Rb independently represent hydrogen; R1 represents: α- or β-branched C3-12alkyl (optionally substituted by hydroxy, OC(O)(C1-6alkyl)), CH2(C3-12cycloalkyl) wherein cycloalkyl is optionally condensed with a benzene ring, C3-12cycloalkyl (optionally substituted by halogen, C1-6alkyl) or R28; R6 represents a phenyl or 5- or 6-phenyl heteroaromatic ring (each of which is optionally substituted by halogen, trifluoromethyl, hydroxy, C1-6alkyl, -C(O)NHR13, -SO2NHR14, C1-6alkoxy, optionally substituted by halogen), C1-6halogenoalkyl, benzodioxolyl, benzothiazolyl substituted by oxo and hydroxy group; R2, R3 and R4 independently represent hydrogen or C1-6alkyl; R29 represents hydrogen; R4 represents hydrogen, hydroxy or C1-6alkyl. The values R13, R14 and R28 are those as specified in the patent claim.

Compounds and compositions of 5-(4-(halogenalkoxy)phenyl)pyrimidin-2-amine as kinase inhibitors / 2455288
In formula (1): R1 means haloalkyl containing 1-6 fluorine atoms; R2 means C1-C6alkyl or halogen; R3 means -L-NR4R5, -X-NR-C(O)R8 or -X-NR-C(O)NR4R5 wherein L means -X-C(O), -(CR2)j, -O(CR2)1-4 or and X means (CR2)j or [C(R)(CR2OR)]; R4 and R5 independently mean H, C1-C6alkyl, halogen-substituted C1-C6alkyl, hydroxy group-substituted C1-C6alkyl, or (CR2)k-R6; R8 independently means (CR2)k-R6 or C1-C6alkyl, or halogen-substituted C1-C6alkyl; R7 means H; alternatively, R4 and R5 together with N atom in each NR4 R5 form a 4-7-member heterocyclic ring containing 1 -2 heteroatoms independently specified in N and O substituted by 0-3 groups R11; R11 means R8, (CR2)k-OR7, CO2R7, (CR2)k-C(O)-(CR2)k-R8, (CR2)kC(O)NR7R7 or (CR2)kS(O)1-2R8; each R means H or C1-C6alkyl; each k is equal to 0-6; and j and m are independently equal to 0-4; provided R1 does not mean trifluoromethoxygroup, provided R3 means C(O)NH2, C(O)NR12R13; wherein R12 and R13 together form piperazinyl; the values of the radical R6 are presented in the patent claim. The invention also refers to the pharmaceutical composition containing said compounds.

Pulmonary surfactant compositions and methods of using them promoting mucus elimination / 2455021
There are disclosed method and composition for intensifying mucus excretion and treating pulmonary disorders, such as cystic fibrosis. They use together with osmotically active substance a synthetic pulmonary surfactant containing one or more pharmaceutically acceptable phospholipids mixed with SP-B polypeptide or its fragment, or polypeptide containing at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide containing a sequence having variable areas of hydrophobic and hydrophilic amino acid residues presented by formula (ZaUb)cZd, wherein surfactant activity of mixed phospholipids and polypeptide higher than that of one phospholipid, has osmolarity varying between 220-1200 mOsm/kg, the concentration of free anions varying between 20-200 mmole/l and the pH value varying between 6.8 and 8.0, and the surfactant provides the pulmonary delivery of a daily dose varying between approximately 20 and 200 mg of total phospholipid equivalent.

Method of treating pharyngitis / 2455013
Invention refers to medicine, namely balneology and balneotherapy, and concerns treating pharyngitis. That is ensured by gargarism with using hydrosulphuric mineral water of the Ust-Kachka resort of total mineralisation 76 g/dm3, hydrogen sulphide concentration 300 mg/dm3, at 18-20°C dissolved 1:5 to final concentration 50 mg/dm3, once a day, daily in the therapeutic course of 10-14 days.

Method of treating bronchial asthma / 2454987
Invention refers to medicine, namely pulmonology, reflexotherapy. The method involves the needle exposure on acupuncture points and the introduction of diprospan. The first, third, sixth, seventh, ninth and twelfth sessions involves the needles covering the acupuncture points P 5 (2) and GI 4 (2). On the second session, the needle exposure involves the points GI 11 (2) in a prone position with hands up, and diprospan 0.25 ml injected in the points V 11 (2) and V 13 (2). The fourth and tenth sessions imply the needle exposure on the points P 5 (2), P 7 (2). The fifth session includes the needle therapy in the points GI 11 (2), and diprospan 0.5 ml is injected in the points V 13 (2). On the eighth session, there is used the needle therapy in the points GI 11 (2) in a prone position with hands up, and also in the points V 11 (2) and V 13 (2). The eleventh session involves the needle exposure on the points GI 11 (2) and V 13 (2).

Pharmaceutical dosage forms and compositions of colon absorbed phenylephrine / 2454225
Invention discloses an orally applicable pharmaceutical composition. The pharmaceutical composition contains a core containing a controlled-release polymer matrix containing hydroxypropyl cellulose and sodium salt of carboxymethyl cellulose, and phenylephrine or its pharmaceutically acceptable salt, and an erodible layer optionally containing phenylephrine or its pharmaceutically acceptable salt. When a subject intakes the composition, the controlled-release polymer matrix containing said ingredients provides a zero or near-zero order of release of phenylephrine or its pharmaceutically acceptable salt, and at least a portion of phenylephrine is colon absorbed. Besides, the pharmaceutical composition may contain one or more additional therapeutically active agents specified in a group consisting of an antihistamine, an analgesic, an antipyretic and a non-steroidal anti-inflammatory agent.

Rectal suppositories for treatment of hemorrhoids, proctitis and other proctological diseases / 2455978
Invention relates to chemical-pharmaceutical industry and represents medication for treatment of hemorrhoids, proctitis and other inflammatory proctological diseases in form of rectal suppository, characterised by the fact that it contains as active substances Juglanex and Tycveolum, as auxiliary substances contains polyethylene glycol 1500 and emulsifier T2, components in medication are in specified ratio in grams per 1 suppository, with weight 2.6 g.

Hygienic lipstick with licorice extract / 2455977
Invention relates to food and medical industry, in particular, production of hygienic lipsticks, possessing anti-inflammatory and wound-healing effect, intended for lip care, elimination of manifestation of dryness, burning, cracks, cheilitis, lip skin maceration. Hygienic lipstick includes bee wax, candelilla wax, carnauba wax, cocoa butter, castor oil, coconut oil, soybean oil, mineral oil, lanolin, oil extract of chamomile, cyclomethicone, glycerin monostearate, paraffin, isopropyl myristate, dry licorice extract, tocopherol acetate, retinol palmitate, nipagin and fragrance.

Method of increasing stability of antiperspirant/deodorant composition fragrance / 2455976
Invention relates to field of cosmetics, in particular, to antiperspirant, deodorants. Composition includes, at least, one active component, selected from one antiperspirant active component and, one deodorant active component; first gel-forming agent, selected from one fatty alcohol and, at least, one soya oil, which has iodine number from more than 0 to approximately 20; and, at least, one organosilicon compound.

Toothpaste / 2455975
Invention relates to field of medicine, namely to dentistry, and can be used as therapeutic-preventive preparation, used for tooth care and oral cavity care. Invention represents toothpaste, which contains abrasive component, binding agent, moisturisers, preservatives, biological additives, functional additives, surface-active substances (SAS), fragrances and water, as SAS paste contains lecithin and betaine surface-active substance, as biological additive - saccharin or maltose or aspartame or sodium cyclamate, essential oils of plants or water-alcohol extracts of medicinal plants, as functional additives - calcium glycerophosphate, soluble calcium salts or sodium fluoride, with specified ratio of components. Claimed toothpaste does not contain sodium laurylsulfate. Tooth application in short terms results in considerable improvement of state of periodontium and oral cavity tissues. Expressed effect appears already on 3-4 day from beginning of its application.

Oral composition containing nonpathogenic microorganisms showing ability to normalise intestinal microflora (versions) / 2453320
Group of inventions refers to pharmaceutical industry and medicine and is applicable for producing and using medical immunobiological preparations containing nonpathogenic microorganisms. The compositions (versions) represent a powder containing substances containing nonpathogenic microorganisms dried up in a culture medium specified in a number: Bifidobacterium bacteria and/or Lactobacillus bacteria, and/or species-specific virulent bacteriophages, and/or species-specific bacteriophages with induced virulence or their combinations with the composition containing target additives able to form a stable foam structure, is characterised by porous structure and fragility, has a relative disintegration shrinkage at least 10 %, equivalent pore diameter 10-110 mcm at particle size no more than 100 mcm and a resting angle less than 50° in the following proportions in 1.0 g of the composition: Bifidobacterium bacteria 106-1010 CFU and/or Lactobacillus bacteria 106-1010 CFU, and/or species-specific virulent bacteriophages of Appelman's lytic activity at least 10-4 with respect to test strains and bacterial isolates recovered from a human body, and/or species-specific bacteriophages of induced virulence of Appelman's lytic activity at least 10-4 with respect to test strains and bacterial isolates recovered from a human body, target additives - the rest.